Immix Biopharma (IMMX) Leases (2024 - 2026)

Quarterly results put Leases at $927728.0 for Q1 2026, down 4.2% from a year ago — trailing twelve months through Mar 2026 was $927728.0 (down 4.2% YoY), and the annual figure for FY2025 was $966917.0, down 2.28%.

Immix Biopharma has reported Leases over the past 3 years, most recently at $927728.0 for Q1 2026.

  • Leases reached $927728.0 in Q1 2026 per IMMX's latest filing, down from $966917.0 in the prior quarter.
  • Across five years, Leases topped out at $1.1 million in Q1 2024 and bottomed at $927728.0 in Q1 2026.
  • Median Leases over the past 3 years was $989471.0 (2024), compared with a mean of $988560.2.
  • Peak annual rise in Leases hit 0.47% in 2025, while the deepest fall reached 8.11% in 2025.
  • Over 3 years, Leases stood at $989471.0 in 2024, then dropped by 2.28% to $966917.0 in 2025, then decreased by 4.05% to $927728.0 in 2026.
  • Business Quant data shows Leases for IMMX at $927728.0 in Q1 2026, $966917.0 in Q4 2025, and $1.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Leases (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 83,048.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 61,822.50
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 285.20 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 1.69 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 189.30 Mn
10 Immix Biopharma 476.17 Mn 476.17 Mn - 927,728.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 927,728.00
Dec 31, 2025 966,917.00
Sep 30, 2025 1.01 Mn
Jun 30, 2025 947,103.00
Mar 31, 2025 968,444.00
Dec 31, 2024 989,471.00
Sep 30, 2024 1.01 Mn
Jun 30, 2024 1.03 Mn
Mar 31, 2024 1.05 Mn